Search

Displaying results 851 - 860 of 1100 in total
  1. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  2. Drug

    Zinc sulfate, unspecified form

    go.drugbank.com/drugs/DB14548
    Approved

    Zinc sulfate is a common zinc supplement in parenteral nutrition.

    Mixtures: Up and Up Ultra Itchy Relief
  3. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] The treatment effect was maintained for up to 12 months.[L2933]

  4. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

  5. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated

  6. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. … Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.

  7. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    Manganese is a transition metal that was first described in the 19th and 20th centuries. It is environmentally abundant, being the fifth most abundant metal and the twelfth most abundant element overall on Earth. Manganese intake primari...

    Mixtures: Trace Elements Injection USP, Cps Capsules
  8. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[

  9. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

  10. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that...